表紙
市場調査レポート

転移性卵巣癌:パイプライン製品の分析

Metastatic Ovarian Cancer - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 253656
出版日 ページ情報 英文 87 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.55円で換算しております。
Back to Top
転移性卵巣癌:パイプライン製品の分析 Metastatic Ovarian Cancer - Pipeline Review, H1 2016
出版日: 2016年04月20日 ページ情報: 英文 87 Pages
概要

転移性卵巣癌は、卵巣から発生する癌ですが、体の他の部位(横隔膜、腸、頤(おとがい)、肝臓、肺など)に転移します。疲労、早期満腹感、腹部膨満、脚のむくみ、排便習慣の変化、排尿習慣の変化、腹痛、息切れなどの症状が見られます。治療は、多くの場合、外科手術、化学療法、放射線療法を併用して行われます。

当レポートでは、転移性卵巣癌に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

転移性卵巣癌の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

転移性卵巣癌:企業で開発中の治療薬

転移性卵巣癌:大学/機関で研究中の治療薬

転移性卵巣癌:パイプライン製品の概況

  • 臨床段階の製品
  • 初期段階の製品

転移性卵巣癌:企業で開発中の製品

転移性卵巣癌:大学/機関で研究中の製品

転移性卵巣癌の治療薬開発に従事している企業

  • Cellceutix Corporation
  • エーザイ
  • F. Hoffmann-La Roche Ltd.
  • Immune Design Corp.
  • Millennium Pharmaceuticals, Inc.
  • Natco Pharma Limited
  • Northwest Biotherapeutics, Inc.
  • 大日本住友製薬
  • VG Life Sciences, Inc.

転移性卵巣癌:治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

転移性卵巣癌:最近のパイプライン動向

転移性卵巣癌:休止中のプロジェクト

転移性卵巣癌:開発が中止された製品

転移性卵巣癌:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7892IDB

Summary

Global Markets Direct's, 'Metastatic Ovarian Cancer - Pipeline Review, H1 2016', provides an overview of the Metastatic Ovarian Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Metastatic Ovarian Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Ovarian Cancer and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Metastatic Ovarian Cancer
  • The report reviews pipeline therapeutics for Metastatic Ovarian Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Metastatic Ovarian Cancer therapeutics and enlists all their major and minor projects
  • The report assesses Metastatic Ovarian Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Metastatic Ovarian Cancer

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Metastatic Ovarian Cancer
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Metastatic Ovarian Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Metastatic Ovarian Cancer Overview
  • Therapeutics Development
    • Pipeline Products for Metastatic Ovarian Cancer - Overview
    • Pipeline Products for Metastatic Ovarian Cancer - Comparative Analysis
  • Metastatic Ovarian Cancer - Therapeutics under Development by Companies
  • Metastatic Ovarian Cancer - Therapeutics under Investigation by Universities/Institutes
  • Metastatic Ovarian Cancer - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Metastatic Ovarian Cancer - Products under Development by Companies
  • Metastatic Ovarian Cancer - Products under Investigation by Universities/Institutes
  • Metastatic Ovarian Cancer - Companies Involved in Therapeutics Development
    • Cellceutix Corporation
    • Eisai Co., Ltd.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd.
    • Immune Design Corp.
    • Millennium Pharmaceuticals, Inc.
    • MolMed S.p.A.
    • Natco Pharma Limited
    • Northwest Biotherapeutics, Inc.
    • Sumitomo Dainippon Pharma Co., Ltd.
    • VG Life Sciences, Inc.
  • Metastatic Ovarian Cancer - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • CMB-305 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DCVax-Direct - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • E-7449 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • emactuzumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • G-305 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • hydroxychloroquine + sorafenib tosylate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • KM-3174 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LV-305 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LY-2780301 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NGR-hTNF - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NRCAN-019 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • orteronel - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OS-2966 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SM-276001 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for Oncology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Metastatic Ovarian Cancer - Recent Pipeline Updates
  • Metastatic Ovarian Cancer - Dormant Projects
  • Metastatic Ovarian Cancer - Discontinued Products
  • Metastatic Ovarian Cancer - Product Development Milestones
    • Featured News & Press Releases
      • Jun 22, 2015: VG Life Sciences Granted Combination Cancer Drug Patent
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Metastatic Ovarian Cancer, H1 2016
  • Number of Products under Development for Metastatic Ovarian Cancer - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Metastatic Ovarian Cancer - Pipeline by Cellceutix Corporation, H1 2016
  • Metastatic Ovarian Cancer - Pipeline by Eisai Co., Ltd., H1 2016
  • Metastatic Ovarian Cancer - Pipeline by Eli Lilly and Company, H1 2016
  • Metastatic Ovarian Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Metastatic Ovarian Cancer - Pipeline by Immune Design Corp., H1 2016
  • Metastatic Ovarian Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016
  • Metastatic Ovarian Cancer - Pipeline by MolMed S.p.A., H1 2016
  • Metastatic Ovarian Cancer - Pipeline by Natco Pharma Limited, H1 2016
  • Metastatic Ovarian Cancer - Pipeline by Northwest Biotherapeutics, Inc., H1 2016
  • Metastatic Ovarian Cancer - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016
  • Metastatic Ovarian Cancer - Pipeline by VG Life Sciences, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Metastatic Ovarian Cancer Therapeutics - Recent Pipeline Updates, H1 2016
  • Metastatic Ovarian Cancer - Dormant Projects, H1 2016
  • Metastatic Ovarian Cancer - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Metastatic Ovarian Cancer, H1 2016
  • Number of Products under Development for Metastatic Ovarian Cancer - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top